VALTOCO®
(diazepam nasal spray) CIV

FREQUENTLY ASKED QUESTIONS ABOUT VALTOCO® (DIAZEPAM NASAL SPRAY)

Please see Important Safety Information, including Boxed Warning, on the back.

FOR MORE INFORMATION:

Visit **www.MaxorSpecialty.com** or call 1-866-629-6779 Monday-Friday, 8 AM to 5 PM CT

FREQUENTLY ASKED QUESTIONS ABOUT VALTOCO® (DIAZEPAM NASAL SPRAY)

1. What is VALTOCO nasal spray?

VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

2. Is VALTOCO a replacement for antiepileptic drugs (AEDs)?

No. Patients still need to take their AEDs; VALTOCO is intended as a rescue medication for patients who experience episodes of frequent seizure activity distinct from their usual seizure pattern.

3. How is VALTOCO dosed?

VALTOCO has specific individualized dosing based on age and weight

6-11 years (0.3 mg/kg)

Weight (kg)	Weight (lb)	Dose (mg)	Given As
10-18	22.0-39.7	5	One **5 mg** nasal spray device in one nostril
19-37	41.9-81.6	10	One **10 mg** nasal spray device in one nostril
38-55	83.8-121.3	15	Two **7.5 mg** nasal spray devices, one in each nostril
56-74	123.5-163.1	20	Two **10 mg** nasal spray devices, one in each nostril

12+ years (0.2 mg/kg)

Weight (kg)	Weight (lb)	Dose (mg)	Given As
14-27	30.9-59.5	5	One **5 mg** nasal spray device in one nostril
28-50	61.7-110.2	10	One **10 mg** nasal spray device in one nostril
51-75	112.4-165.3	15	Two **7.5 mg** nasal spray devices, one in each nostril
76 and up	167.6 and up	20	Two **10 mg** nasal spray devices, one in each nostril

A second dose may be given at least 4 hours after initial dose, if needed, using a new blister pack.

4. Can my patients carry VALTOCO with them?

Yes, VALTOCO's small, portable, and discreet packaging is intended for patients to carry with them in their pocket or purse—whenever, wherever. It does not need to be refrigerated and is designed for prompt administration by anyone.

5. Is VALTOCO available now?

Yes, VALTOCO is currently available in 4 treatment doses (5 mg, 10 mg, 15 mg, 20 mg) through Maxor Specialty Pharmacy.

6. What is the prescribing and e-prescribing process for VALTOCO? Please be sure to include dosage, number of boxes, and amount of refills.

You can submit VALTOCO prescriptions to Maxor Specialty Pharmacy via fax at 866-217-8034, or e-prescribe to:

Maxor Specialty Pharmacy
216 S Polk, Amarillo, TX 79101
Ph: 1-866-629-6779
NCPDPID: 5905661

If you are having trouble finding "Maxor Specialty Pharmacy" in the system, you may locate using the pharmacy phone (1-866-629-6779) or ZIP code (79101).

For ease, be sure to bookmark "Maxor Specialty Pharmacy" as a favorite in your e-prescribing system for future use.

Please ensure all required patient information is included to avoid delays in processing the prescription. Don't forget to include: patient first name, last name, date of birth, gender, and pharmacy benefit information: BIN, PCN, Group ID#.

A Maxor representative will contact you within 24 hours if prior authorization or clarification is needed.

7. What can patients expect to find in each box?

Each box of VALTOCO contains 2 blister packs, an Instructions for Use guide, and the full Prescribing Information with Medication Guide. Each box contains two doses.

For 5 mg or 10 mg, each blister pack contains 1 VALTOCO nasal spray device, which is 1 full dose of VALTOCO.

For 15 mg or 20 mg, each blister pack contains 2 nasal spray devices. Both devices must be used for 1 dose.

8. Is there a copay savings program?

Eligible patients may pay as little as $20 with the VALTOCO copay card. To find out more about the program and how to get a copay card, patients can call 1-866-629-6779.

Subject to eligibility. For private insurance programs only.

9. How can I get more information about VALTOCO?

To learn more about VALTOCO, or to request a visit from your local Neurelis representative, go to VALTOCOHCP.com.

VALTOCO® (diazepam nasal spray) CV

10. How would I write a VALTOCO prescription?



Rx

Steve J. Johnson MD
ABC Hospital, Neurology Department
Main Street, USA
(555) 555-4242

Date: March 15, 2020

Patient: Erin R. Smith
123 Bay Ave

Valtoco (diazepam nasal spray) ____mg

use as instructed
prn for seizure cluster

dispense #___ boxes / month

Refill: ___

Steve J. Johnson MD
DEA# C91234569

Insert dose:
5 mg, 10 mg, 15 mg, or 20 mg

Insert number of boxes;
each box contains two rescue doses

Insert number of refills

FOR MORE INFORMATION:

Visit **www.MaxorSpecialty.com** or call 1-866-629-6779 Monday-Friday, 8 AM to 5 PM CT

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

VALTOCO® (diazepam nasal spray) CIV

IMPORTANT SAFETY INFORMATION

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

- **Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate**
- **Limit dosages and durations to the minimum required**
- **Follow patients for signs and symptoms of respiratory depression and sedation**

Contraindications: VALTOCO is contraindicated in patients with:

- Known hypersensitivity to diazepam
- Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to a healthcare provider.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gasping syndrome," can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

US-PRC-20-00202 06/2020

NEURELIS